newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL

BIAFBIAFW
  • bioAffinity Technologies & AvMEDICAL debuted their federal distribution collaboration for the CyPath Lung test to over 300 VA leaders, administrators, & physicians at the NAVREF 2026 Annual Conference in Arlington, Virginia.
  • The new distribution agreement utilizes AvMEDICAL's procurement channels & government contracting expertise to expand access to CyPath Lung within the federal healthcare market.
  • Maria Zannes, bioAffinity President & CEO, stated the partnership aims to improve healthcare outcomes for veterans & expand awareness of the noninvasive lung cancer test.
  • Lung cancer affects approximately 7,700 veterans annually, creating a significant health burden that the collaboration seeks to address through earlier detection.
  • CyPath Lung is a noninvasive sputum test using flow cytometry & AI to provide actionable data for physicians evaluating high-risk patients with small indeterminate lung nodules.
  • Clinical trial data for CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, & 99% negative predictive value (NPV) in detecting lung cancer.
  • bioAffinity also presented CyPath Lung at the GO2 for Lung Cancer Centers of Excellence conference in San Diego to extend outreach to the lung cancer screening community.
  • GO2 for Lung Cancer partners with the VA to increase screening awareness, provide resources for implementation, & operate a national network of over 700 screening centers of excellence.
  • AvMEDICAL is a Service-Disabled Veteran-Owned Small Business (SDVOSB) that has doubled its product portfolio since 2020 to include advanced laboratory & respiratory testing solutions.
  • CyPath Lung is marketed as a Laboratory Developed Test (LDT) under CLIA oversight & is intended to complement, not replace, other clinical diagnostic findings.
  • bioAffinity Technologies is a member of NAVREF's Industry Partner Consortium to advance VA research & develop noninvasive diagnostic solutions.
  • The press release includes forward-looking statements regarding anticipated benefits of the distribution agreement, potential growth in demand, & risks related to government contracts, CLIA compliance, & financing.